Drug-Coated Balloons in Coronary Artery Disease: Engineering, Pharmacology, and the Mechanisms Behind Angiographic Outcomes - PubMed
12 hours ago
- #Drug-coated balloons
- #Percutaneous coronary intervention
- #Coronary artery disease
- Drug-coated balloons (DCBs) offer a unique drug-delivery method, relying on brief inflation for therapeutic efficacy.
- Paclitaxel-based DCBs outperform sirolimus-coated platforms in drug uptake, retention, and clinical outcomes due to paclitaxel's lipophilicity and microtubule binding.
- Sirolimus requires engineered delivery systems like crystalline matrices or nanoparticles to enhance its effectiveness.
- DCB therapy's success depends on technology and drug properties, not just drug load, influencing angiographic outcomes.
- Understanding DCB mechanisms is crucial for device selection and developing next-generation technologies for consistent clinical performance.